Abstract
Urolithiasis is a disorder of kidneys in which stones formation occur due to the excessive deposition of minerals in the urinary tract. It affects 12% of the population worldwide. Salvia hispanica seeds are rich source of quercetin which has preventive role in renal stone formation. The study objective was to explore scientifically the anti-urolithiatic effect of Salvia hispanica seed's methanol extract using in vitro and in vivo urolithiasis models. For in-vitro study nucleation, growth and aggregation assays were performed. In vivo study was performed on rats and they were divided into six groups (n=6). Group-I was given vehicle only. Group-II was disease control, treated with 0.75% EG in drinking water which triggered urolithiasis. Groups-III received cystone (750 mg/kg, orally). Groups IV-VI were treated with extract at 100, 300 and 700 mg/kg doses orally once daily. Groups III-VI additionally received 0.75% EG in drinking water. In vitro study revealed concentration dependent increase in percentage inhibition of crystal's nucleation, growth and aggregation. In vivo study revealed anti-urolithiatic activity by lowering oxalate, calcium, phosphate, sodium and potassium levels in the urine and the serum uric acid, blood urea nitrogen, total proteins and total albumin. Salvia hispanica seeds are good alterative of allopathic anti-urolithiatic drugs to treat urolithiasis.
Highlights
Urolithiasis is a type of urinary system disorder in which crystals development occur when minerals get deposited in the renal, urinary bladder or ureter (Mamillapalli et al 2016a)
Urolithiasis develops when inhibitors and promotors of kidney stones lose their balance in the kidneys (Gupta et al 2011, Alelign & Petros 2018)
It has been reported that 80% renal stones are composed of calcium oxalate and calcium phosphate, 10% are struvite containing magnesium ammonium phosphate
Summary
Urolithiasis is a type of urinary system disorder in which crystals development occur when minerals get deposited in the renal, urinary bladder or ureter (Mamillapalli et al 2016a). Urolithiasis develops when inhibitors (e.g. magnesium) and promotors (e.g. uric acid) of kidney stones lose their balance in the kidneys (Gupta et al 2011, Alelign & Petros 2018). The drug related renal stones are caused by uric acid (9%) and cystine or ammonium acid urate (1%) (Coe et al 2005, Divakar et al 2010). The worldwide prevalence of urolithiasis is recorded as 12% and it affects both male and female of age 20 to 49 years (Alelign & Petros 2018). It is 2 to 4 times less common in women than in men (Sofia & Walter 2016, Alelign & Petros 2018). The non-pharmacological and pharmacological therapies are available but infertility as major side effect and 50% to 80% relapse rats diverted attention of researchers to find out new drugs having minor side effects and minimum relapse
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
